Trends in MDS and AML from ASH 2023

被引：0
|
作者：
Pfeilstoecker, Michael [1 ]
机构：
[1] Hanusch Hosp, Med Dept 3, H Collinstr 30, A-1140 Vienna, Austria
来源：
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY | 2024年 / 17卷 / 03期
关键词：
Acute myeloid leukemia; Myelodysplastic neoplasms; Clonal hematopoiesis; Targeted molecular therapy; Allogeneic transplantation;
D O I：
10.1007/s12254-024-00984-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Presentations in the field of clonal myeloid diseases from the 65th American Society of Hematology conference provided insights into future therapeutic approaches especially for the subset of older patients. While new drugs and concepts for acute myeloid leukemia need further work before clinical implementation, some data on myelodysplastic neoplasms providing new treatment options for transfusion-dependent low-risk patients are already practice-changing.
引用
收藏
页码：178 / 181
页数：4
相关论文
共 50 条
  • [31] MDS AND AML: HOW TO DEFINE COMPLEXITY
    Schlegelberger, B.
    Goehring, G.
    Niemeyer, C.
    CELLULAR ONCOLOGY, 2010, 32 (03) : 166 - 166
  • [32] MLL gene amplification in MDS/AML
    Papenhausen, PR
    Tepperberg, JH
    Mowrey, PN
    Turk, K
    Gadi, IK
    AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (04) : A77 - A77
  • [33] Advances in MDS/AML and inositide signalling
    De Stefano, Alessia
    Marvi, Maria Vittoria
    Fazio, Antonietta
    McCubrey, James A.
    Suh, Pann-Ghill
    Ratti, Stefano
    Ramazzotti, Giulia
    Manzoli, Lucia
    Cocco, Lucio
    Follo, Matilde Y.
    ADVANCES IN BIOLOGICAL REGULATION, 2023, 87
  • [34] MYC overexpression is associated with an early disease progression from MDS to AML
    Gajzer, David
    Logothetis, Constantine N.
    Sallman, David A.
    Calon, Gregoire
    Babu, Abida
    Chan, Onyee
    Vincelette, Nicole D.
    Volpe, Virginia O.
    Al Ali, Najla H.
    Basra, Pukhraz
    Talati, Chetasi
    Kuykendall, Andrew T.
    Mo, Qianxing
    Padron, Eric
    Sweet, Kendra
    Komrokji, Rami S.
    Lancet, Jeffrey E.
    Yun, Seongseok
    Zhang, Ling
    LEUKEMIA RESEARCH, 2021, 111
  • [35] Transformation from MDS to AML in a patient with Rothmund-Thomson syndrome
    Özbas, Hasan Mucahit
    Cinar, Esma
    Oguz, Isil Deniz
    Baylan, Alev Gul
    Cubukcu, Damla
    Dikbas, Oguz
    AKTUELLE DERMATOLOGIE, 2023, 49 (06) : 268 - 272
  • [36] NUP98 is a target for chromosomal translocations in therapy related AML and MDS (t-AML/MDS).
    Ahuja, HG
    Raza-Egilmez, SZ
    Jain-Sait, SN
    Grossi, M
    Higgins, MJ
    Shows, TB
    Felix, CA
    Aplan, PD
    BLOOD, 1998, 92 (10) : 70A - 70A
  • [37] ASH 2023
    Zojer, Niklas
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2024, 17 (03) : 153 - 153
  • [38] Arsenic trioxide (ATO) and gemtuzumab ozogamicin (GO) in high-risk MDS or AML arising from MDS
    Sekeres, M. A.
    Kalaycio, M. E.
    Erba, H. P.
    Sobecks, R.
    Advani, A.
    Chan, J.
    Maciejewski, J. P.
    LEUKEMIA RESEARCH, 2007, 31 : S125 - S125
  • [39] AML/TMDS与MDS-AML的对比研究
    张德胜
    马灿华
    宫奇林
    肿瘤防治杂志, 2003, (03) : 292 - 293
  • [40] AML1 and Evi1: coconspirators in MDS/AML?
    Graubert, Timothy
    BLOOD, 2008, 111 (08) : 3916 - 3917
12345